Neuromodulation Start-Ups: Abundant Funding, Slow Exits
This article was originally published in Start Up
Executive Summary
The field of neuromodulation has produced numerous start-ups and a decent amount of fundraising activity over the past six years, but exits are scarce.
You may also be interested in...
Newly Public Medtechs Gain In Share Price, Market Cap
The device IPO class of 2014 gained on share price, with several outperforming by more than 100%, and market caps for larger companies have grown at a rapid pace.
Device/Diagnostics Quarterly Deal Statistics, Q4 2014
Q4 device financing reached $902 million versus Q3’s $734 million, while device M&A dollar volume increased $19 billion, from Q3’s $4.9 billion. Diagnostics companies raised $750 million, an 85% rise over the previous quarter’s $405 million; although diagnostics M&A totaled just $1 billion, it was the most deal-active quarter of 2014 with 11 transactions.
Late-Stage Venture Continues To Dominate Medtech Financing
Device start-ups raised $1.7 billion in 2013, and approximately 75% of the total was from Series C or later rounds, a sign that investors are still more comfortable making investments in more advanced companies.